Tuberculosis among HIV-infected patients in Stockholm, Sweden, 1987–2010: Treatment outcomes and adverse reactions

References

• World Health Organization. TB/HIV Facts 2012–2013. WHO; 2012. Available at: http://www.who.int/tb/publications/factsheet_tbhiv.pdf (accessed 5 March 2013).
   Google Scholar
• Smittskyddsinstitutet. Epidemiologisk årsrapport 2011. Report No. 2012-15-6. Stockholm: Elanders Sverige, AB; 2012. pp 1–84.
   Google Scholar
• Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22–9.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43: 27–34.
   PubMed Web of Science ®Google Scholar
• Lodi S, del Amo J, d’Arminio Monforte A, Abgrall S, Sabin C, Morrison C, et al. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax 2013;68:207–13.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697–706.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365: 1492–501.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365: 1482–91.
   PubMed Web of Science ®Google Scholar
• Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471–81.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva: WHO; 2010. pp 1–160.
   Google Scholar
• Arbex MA, de Castro Lima Varella M, de Siqueira HR, de Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol 2010;36:626–40.
   PubMed Web of Science ®Google Scholar
• Santos Dos AP, Pacheco AG, Staviack A, Golub JE, Chaisson RE, Rolla VC, et al. Safety and effectiveness of HAART in tuberculosis–HIV co-infected patients in Brazil. Int J Tuberc Lung Dis 2013;17:192–7.
   Google Scholar
• Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002;16:75–83.
   PubMed Web of Science ®Google Scholar
• Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005;5:361–73.
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008;335:126–36.
   PubMed Web of Science ®Google Scholar
• Josephson F, Albert J, Flamholc L, Gisslén M, Karlström O, Moberg L, et al. Treatment of HIV infection: Swedish recommendations 2009. Scand J Infect Dis 2009;41:788–807.
   PubMed Web of Science ®Google Scholar
• Wickham H. ggplot2: elegant graphics for data analysis. Springer; 2009. Available at: http://had.co.nz/ggplot2/book (accessed 10 August 2013).
   Google Scholar
• Kherad O, Herrmann FR, Zellweger JP, Rochat T, Janssens JP. Clinical presentation, demographics and outcome of tuberculosis (TB) in a low incidence area: a 4-year study in Geneva, Switzerland. BMC Infect Dis 2009;9:217.
   PubMed Web of Science ®Google Scholar
• Metcalfe JZ, Porco TC, Westenhouse J, Damesyn M, Facer M, Hill J, et al. Tuberculosis and HIV co-infection, California, USA, 1993–2008. Emerg Infect Dis 2012;19:400–6.
   Google Scholar
• Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010;50:1288–99.
   PubMed Web of Science ®Google Scholar
• Chunpongthong P, Ko ZZ, Yeekian C, Luvira V, Pitisuttithum P. Outcomes of antituberculosis treatments at 18 months follow-up in TB–HIV co-infected patients on ART: a retrospective review of 166 cases. J Med Assoc Thai 2011;94:664–70.
   Google Scholar
• Limmahakhun S, Chaiwarith R, Nuntachit N, Sirisanthana T, Supparatpinyo K. Treatment outcomes of patients co-infected with tuberculosis and HIV at Chiang Mai University Hospital, Thailand. Int J STD AIDS 2012;23:414–8.
   Google Scholar
• Nansera D, Bajunirwe F, Elyanu P, Asiimwe C, Amanyire G, Graziano FM. Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda. Int J Tuberc Lung Dis 2012;16:1371–6.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2013. pp 1–267. Available at: http://aidsinfo.nih.gov/ContentFiles/Adultand (accessed 5 March 2013).
   Google Scholar
• Loeliger A, Suthar AB, Ripin D, Glaziou P, O’Brien M, Renaud-Thery F, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?Int J Tuberc Lung Dis 2012;16:6–15.
   PubMed Web of Science ®Google Scholar
• Lorent N, Sebatunzi O, Mukeshimana G, Van den Ende J, Clerinx J. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. PLoS One 2011;6:e19566.
   Google Scholar
• Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009;20:339–45.
   PubMed Web of Science ®Google Scholar
• van der Werf MJ, Langendam MW, Huitric E, Manissero D. Knowledge of tuberculosis-treatment prescription of health workers: a systematic review. Eur Respir J 2012;39: 1248–55.
   Google Scholar
• Wannheden C, Westling K, Savage C, Sandahl C, Ellenius J. HIV and tuberculosis coinfection: a qualitative study of treatment challenges faced by care providers. Int J Tuberc Lung Dis 2013;17:1029–35.
   Google Scholar
• Helleberg M, Häggblom A, Sönnerborg A, Obel N. HIV care in the Swedish–Danish HIV Cohort 1995–2010, closing the gaps. PLoS One 2013;8:e72257.
   PubMed Web of Science ®Google Scholar
• Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687–93.
   PubMed Web of Science ®Google Scholar
• Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007;11:828–37.
   PubMed Web of Science ®Google Scholar